Health
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical study results for mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1) were orally presented (Abstract #
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical study results for mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1) were orally presented (Abstract #: 306-OR) at the 85th Scientific Sessions of the American Diabetes Association (ADA), with Dr. Lei Qian from Innovent Biologics, as the presenter. The DREAMS-1 clinical study met its primary endpoint and all key secondary endpoints in July 2024. Mazdutide demonstrated dual benefits in glycemic control and weight loss, along with comprehensive improvements in cardiovascular, renal, and metabolic indicators. These findings provide important evidence-based medical support for the use of next-generation GCG/GLP-1 receptor agonists in treating T2D. In August 2024, mazdutide's NDA for glycemic control of T2D patients was accepted by China's National Medical Products Administration (NMPA) for review. It is expected to offer a better treatment option for Chinese T2D patients soon.","length":1360,"tagName":"p"},{"type":"image","alt":"Oral Presentation at 2025 ADA","displaySize":"","headline":null,"caption":"Oral Presentation at 2025 ADA","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":300,"url":"https://media.zenfs.com/en/prnewswire.com/8926b2ec06606debb3e95458fb4a76d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LGhmEePQvpBBWe.qvu2YIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8926b2ec06606debb3e95458fb4a76d4","width":400,"height":300}},"href":"https://mma.prnewswire.com/media/2717795/image.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"DREAMS-1 (ClinicalTrials.gov, NCT05628311) enrolled 319 Chinese participants with T2D inadequately controlled by diet and exercise alone (mean age 50.4 years, mean baseline HbA1c 8.24%, mean baseline body weight 77.7 kg). Participants were randomized to receive mazdutide 4 mg, mazdutide 6 mg or placebo for 24 weeks. The pr...